



JOURNAL OF SCIENTIFIC RESEARCH IN ALLIED SCIENCES

Contents available at: www.jusres.com



A Critical Review of Pharmacological Interventions in Chronic Pain Management

Ankit Dhakad, Pragya Sharma, Dr. Rita Mourya, Dr. Shailesh Jain

SAM College of Pharmacy, SAM Global University, Bhopal

ARTICLE INFO

ABSTRACT

REVIEW ARTICLE

Article History

Received: January 2025

Accepted: March 2025

Keywords:

Chronic pain;
Pharmacological
interventions;
Neuropathic pain; Opioid
analgesics; Non-opioid
analgesics; Adjunctive
medications

This critical review examines pharmacological interventions for chronic pain management, synthesizing current evidence on efficacy, safety, and implementation strategies. Chronic pain affects approximately 1.5 billion people worldwide, representing a significant healthcare burden with profound impacts on quality of life and functioning. We analyze the pathophysiological mechanisms of nociceptive, neuropathic, and mixed pain types, highlighting their implications for treatment selection. Evidence supports a mechanism-based approach to pharmacotherapy, with non-opioid analgesics showing moderate effectiveness for nociceptive pain while anticonvulsants and antidepressants demonstrate superior efficacy for neuropathic conditions. Opioid analgesics provide significant short-term relief but have limited long-term efficacy and substantial safety concerns. Combination therapy targeting multiple pain mechanisms yields superior outcomes compared to monotherapy, supporting multimodal approaches. Patient-centered care incorporating comprehensive assessment, personalized medicine principles, and multidisciplinary integration optimizes treatment outcomes. Regulatory and ethical considerations significantly impact prescribing practices, necessitating a balanced approach to risk management and medication access. Future research priorities include comparative effectiveness studies, precision medicine approaches, and novel analgesic development to address current treatment limitations. This review provides clinicians with evidence-based recommendations for optimizing pharmacological management of chronic pain while identifying critical knowledge gaps requiring further investigation.

*Corresponding Author:
Ms. Pragya Sharma

2025, www.jusres.com

INTRODUCTION

Definition and Epidemiology of Chronic Pain

Chronic pain is defined as persistent or recurrent pain lasting longer than three months or beyond the normal tissue healing time [1]. This complex condition affects approximately 1.5 billion people worldwide, representing a significant global health challenge [2]. The

prevalence varies across populations, with estimates suggesting that 20-35% of adults experience chronic pain, with higher rates among older individuals and those with comorbidities [3]. Unlike acute pain, which serves as a protective mechanism, chronic pain often persists without serving a physiological purpose, becoming a disease entity itself rather

than merely a symptom [4]. The multifactorial nature of chronic pain encompasses biological, psychological, and social dimensions, complicating both diagnosis and treatment approaches [5].

Impact of Chronic Pain on Quality of Life

The burden of chronic pain extends far beyond physical discomfort, profoundly affecting multiple aspects of patients' lives. Studies demonstrate significant reductions in functional capacity, with 50-70% of chronic pain sufferers reporting limitations in daily activities [6]. Psychological consequences include increased rates of depression (30-40%) and anxiety disorders (20-30%) compared to the general population [7]. Sleep disturbances affect up to 65% of patients, creating a cyclical relationship where pain disrupts sleep, and poor sleep exacerbates pain perception [8]. Socioeconomically, chronic pain leads to reduced work productivity, with approximately 50 million lost workdays annually in the United States alone [9]. The economic impact includes direct healthcare costs estimated at \$560-635 billion annually, surpassing costs associated with heart disease, cancer, and diabetes [10].

Rationale for Pharmacological Management

Pharmacological interventions remain fundamental in chronic pain management despite evolving approaches. The complex neurobiological mechanisms underlying pain persistence necessitate targeted therapeutic strategies that modulate pain transmission and perception [11]. Evidence supports a multimodal approach, with pharmacotherapy serving as a cornerstone while acknowledging its limitations when used in isolation [12]. Compound analgesics demonstrate superior pain reduction compared to single-agent therapies in randomized controlled trials, supporting rational polypharmacy approaches [13]. The heterogeneity of pain mechanisms across different chronic pain conditions underscores the need for mechanism-based pharmacological selection rather than symptom-based prescribing [14]. While non-pharmacological options show promise, particularly in specific populations,

effective pain management often requires judicious medication use to achieve meaningful pain reduction and functional improvement [15].

Pathophysiology of Chronic Pain Nociceptive Pain Mechanisms

Nociceptive pain arises from actual or threatened damage to non-neural tissues, involving the normal activation of nociceptors responsive to noxious stimuli [16]. This form of pain typically results from inflammation or mechanical damage that activates peripheral nociceptors through the release of inflammatory mediators including prostaglandins, bradykinin, and cytokines [17]. Signal transduction occurs via specialized sensory neurons, primarily A δ and C-fibers, which transmit impulses to second-order neurons in the dorsal horn of the spinal cord [18]. Central sensitization, characterized by increased excitability of neurons in the central nervous system, plays a crucial role in the transition from acute to chronic nociceptive pain states [19]. Persistent nociceptive signaling leads to neuroplastic changes in the dorsal horn, including altered gene expression and receptor function, contributing to hyperalgesia and allodynia [20].

Neuropathic Pain Mechanisms

Neuropathic pain results from direct damage or disease affecting the somatosensory nervous system, involving distinct pathophysiological processes compared to nociceptive pain [21]. Following nerve injury, ectopic activity develops in damaged axons and dorsal root ganglia, creating spontaneous pain independent of nociceptive input [22]. Peripheral sensitization occurs through altered sodium and calcium channel expression and function, contributing to hyperexcitability [23]. Centrally, disinhibition results from reduced GABAergic and glycinergic inhibitory control, while glutamatergic excitatory transmission is enhanced [24]. Neuroimmune interactions, particularly microglial activation, release pro-inflammatory cytokines that further sensitize

neurons and perpetuate pain signaling [25]. These mechanisms explain why neuropathic pain often responds poorly to conventional analgesics and requires targeted approaches such as anticonvulsants or antidepressants [26].

Psychogenic and Mixed Pain Components

Psychogenic pain involves complex interactions between psychological factors and physiological pain processing, though the term has evolved toward recognition of the neurobiological basis of all pain experiences [27]. Neuroimaging studies reveal that psychological factors significantly modulate activity in pain processing regions, including the anterior cingulate cortex, insula, and prefrontal cortex [28]. Stress-induced analgesia or hyperalgesia occurs through alterations in descending pain modulatory pathways involving noradrenergic and serotonergic systems [29]. Most chronic pain conditions feature mixed mechanisms, with nociceptive, neuropathic, and psychogenic components interacting to create complex clinical presentations [30]. This understanding has led to the concept of "nociplastic pain," reflecting altered nociception despite no clear evidence of tissue damage or nerve lesion [31]. The mixed nature of chronic pain underscores the necessity for comprehensive assessment and multifaceted treatment approaches addressing biological, psychological, and social dimensions simultaneously [32].

EVIDENCE-BASED EVALUATION OF PHARMACOLOGICAL OPTIONS

Efficacy of Common Interventions

Non-opioid analgesics demonstrate variable efficacy across chronic pain conditions. Acetaminophen shows modest benefits in osteoarthritis with a number-needed-to-treat (NNT) of 4-5 but limited effectiveness in low back pain [33]. NSAIDs provide superior pain reduction in inflammatory conditions, with COX-2 selective agents offering comparable analgesia to traditional NSAIDs (30-40% pain reduction) without significant efficacy differences between agents [34]. Opioid analgesics initially demonstrate significant pain

reduction (50-60%) in controlled trials, but long-term efficacy is compromised by tolerance development, with systematic reviews indicating diminishing benefits beyond 3 months [35]. Antidepressants, particularly duloxetine and amitriptyline, show consistent efficacy in neuropathic conditions and fibromyalgia, providing clinically significant pain reduction (NNT 3-4) independent of their antidepressant effects [36]. Anticonvulsants exhibit condition-specific efficacy, with gabapentinoids demonstrating superior outcomes in postherpetic neuralgia and diabetic neuropathy compared to other neuropathic conditions [37].

Safety Profiles and Adverse Effects

Medication classes exhibit distinct safety concerns requiring careful risk assessment. Acetaminophen, while generally well-tolerated, carries dose-dependent hepatotoxicity risk, with 44% of severe liver injuries being inadvertent overdoses [38]. NSAIDs present gastrointestinal complications (1-2% annual incidence of serious events), cardiovascular risks (40% increased risk of adverse cardiac events), and renal impairment, particularly in elderly patients and those with comorbidities [39]. Opioid therapy entails significant risks including respiratory depression (0.5-2% incidence), dependence (21-29% of prescribed patients), addiction (8-12%), and overdose mortality, with risk factors including dose escalation and concurrent benzodiazepine use [40]. Antidepressants exhibit class-specific adverse effects, with TCAs causing anticholinergic effects and cardiac conduction disturbances, while SNRIs predominantly cause nausea, dizziness, and hypertension [41]. Anticonvulsants commonly produce sedation, dizziness, and cognitive impairment, with weight gain affecting 5-15% of patients and rare but serious effects including Stevens-Johnson syndrome [42].

Cost-Effectiveness Considerations

Economic evaluations reveal significant variations in cost-effectiveness across interventions. Generic NSAIDs and

acetaminophen present favorable cost-effectiveness profiles with incremental cost-effectiveness ratios (ICERs) below \$10,000 per quality-adjusted life year (QALY) for moderate pain reduction [43]. Opioid therapy demonstrates poor long-term cost-effectiveness due to monitoring requirements, adverse effect management, and diminishing efficacy, with ICERs exceeding \$50,000/QALY beyond six months of treatment [44]. Novel anticonvulsants and antidepressants show intermediate cost-effectiveness, with pregabalin and duloxetine demonstrating ICERs of \$15,000-\$30,000/QALY in neuropathic pain conditions [45]. Multimodal approaches integrating lower-cost medications with targeted adjuvants provide superior economic outcomes compared to single high-cost interventions [46]. Indirect costs, including productivity losses and caregiver burden, significantly impact overall economic assessments, with effective pain management potentially offsetting healthcare expenditures through functional improvements and reduced disability [47].

INDIVIDUALIZED APPROACH TO PAIN MANAGEMENT

Patient Assessment and Selection Criteria

Comprehensive patient evaluation forms the foundation for appropriate pharmacological selection. Standardized pain assessment tools including the Brief Pain Inventory and McGill Pain Questionnaire quantify pain dimensions while functional measures evaluate impact on activities of daily living [48]. Risk stratification instruments such as the Opioid Risk Tool and SOAPP-R identify patients at elevated risk for medication misuse, guiding monitoring intensity and prescribing decisions [49]. Detailed pain characterization distinguishes nociceptive, neuropathic, and mixed mechanisms through validated screening tools like painDETECT and DN4, directing mechanism-based pharmacotherapy [50]. Assessment must address psychological comorbidities, with 40-50% of chronic pain patients experiencing depression or anxiety that significantly influences treatment outcomes and requires

concurrent management [51]. Age-related considerations include altered pharmacokinetics and increased adverse effect susceptibility in elderly patients, necessitating adjusted dosing strategies and vigilant monitoring [52].

Personalized Medicine in Pain Management

Emerging pharmacogenomic approaches enable tailored analgesic selection based on individual genetic profiles. Cytochrome P450 enzyme variants (particularly CYP2D6, CYP2C9, and CYP3A4) significantly impact opioid and NSAID metabolism, with poor metabolizers experiencing either reduced efficacy or increased toxicity depending on whether active drug or active metabolites mediate effects [53]. Genetic polymorphisms in the μ -opioid receptor gene (OPRM1) predict variability in opioid responsiveness and side effect profiles, potentially allowing pre-emptive identification of likely responders [54]. Catechol-O-methyltransferase (COMT) variations influence both pain perception and analgesic response to opioids and adjuvants, explaining up to 10-15% of interindividual variability in pain sensitivity [55]. Voltage-gated sodium channel mutations, particularly SCN9A and SCN10A, predict differential responses to sodium channel blocking medications, offering potential precision targets for neuropathic pain [56]. Integration of genetic information with clinical phenotyping improves treatment outcomes through algorithm-based medication selection, though implementation barriers include cost, accessibility, and provider education [57].

Multidisciplinary Integration of Pharmacotherapy

Effective pharmacological management requires coordination within broader treatment frameworks. Multidisciplinary pain management programs incorporating medication optimization, physical therapy, psychological interventions, and occupational rehabilitation demonstrate superior outcomes compared to medication alone, with 30% greater improvement in pain scores and functional

measures [58]. Pharmacist involvement in medication management improves appropriate prescribing, with collaborative care models reducing high-risk medication combinations by 45% and improving adherence to recommended therapies [59]. Synchronized care delivery between primary care providers, pain specialists, mental health professionals, and physical therapists facilitates regular reassessment of medication efficacy and side effects, allowing timely adjustments [60]. Patient education regarding realistic expectations, proper medication use, and self-management strategies enhances treatment adherence and outcomes, with structured education programs reducing medication misuse by 30-40% [61]. Regular reassessment using standardized outcome measures enables evidence-based adjustments to pharmacotherapy, preventing inappropriate continuation of ineffective treatments while optimizing beneficial regimens [62].

REGULATORY AND ETHICAL CONSIDERATIONS

Prescribing Guidelines and Compliance

Professional organizations have developed evidence-based guidelines to standardize chronic pain management approaches. The CDC Guideline for Prescribing Opioids for Chronic Pain recommends non-opioid therapies as first-line treatment, with opioid initiation only after thorough risk-benefit assessment and at lowest effective doses [63]. Compliance varies significantly, with studies showing 35-65% adherence to key recommendations including risk assessment, treatment agreements, and urine drug monitoring [64]. Prescription Drug Monitoring Programs (PDMPs) have been implemented in all 50 U.S. states, with mandatory utilization laws associated with 12-18% reduction in opioid prescribing and 8-15% decrease in multiple provider episodes [65]. Regulations governing controlled substances have evolved from the Controlled Substances Act of 1970 to include the SUPPORT Act of 2018, expanding

telehealth options while imposing stricter monitoring requirements [66]. International variations in regulatory frameworks create significant disparities in pain management approaches, with some countries maintaining highly restrictive opioid access while others implement balanced policies addressing both pain treatment and misuse prevention [67].

Balancing Access with Risk Management

Stringent regulations intended to reduce misuse have created barriers to legitimate pain treatment. Surveys indicate 48-62% of pain specialists report reluctance to prescribe indicated opioid therapy due to regulatory concerns, while 35% of patients report difficulty filling valid prescriptions [68]. Risk management strategies including treatment agreements, urine drug testing, and prescription limits demonstrate variable effectiveness, with modest reductions in misuse but significant burden on healthcare systems and patients [69]. Vulnerable populations including elderly, minority, and rural patients disproportionately experience impaired access, with disparities in pain assessment and treatment options that compound existing healthcare inequities [70]. Stepped care approaches implementing progressive risk mitigation proportionate to identified risk factors optimize resource allocation while minimizing barriers for low-risk patients [71]. Educational initiatives targeting both providers and patients show promise in improving appropriate access while reducing high-risk prescribing patterns, with academic detailing programs demonstrating 15-20% improvements in guideline-concordant care [72].

Ethical Dilemmas in Pain Management

Clinicians face complex ethical challenges in balancing pain relief against potential harms. Patient autonomy in treatment decisions sometimes conflicts with non-maleficence principles, particularly when patients request high-risk treatments despite medical recommendations [73]. Justice

considerations arise from inequitable pain management across populations, with studies demonstrating that racial/ethnic minorities receive 30-40% less analgesic medication than white counterparts with identical conditions [74]. Resource allocation ethics become relevant as healthcare systems implement cost-containment measures affecting access to expensive pain interventions, creating tensions between individual patient needs and population health priorities [75]. Informed consent processes for chronic pain treatments often inadequately address long-term risks, with only 25-30% of patients demonstrating comprehensive understanding of prescribed medication risks [76]. End-of-life pain management presents particular ethical complexity, with clinicians navigating concerns about hastening death through aggressive symptom management despite established ethical frameworks supporting comfort prioritization [77].

CONCLUSION AND CLINICAL IMPLICATIONS

Summary of Key Findings

Evidence demonstrates that effective chronic pain management requires individualized, mechanism-based approaches rather than symptom-focused prescribing. Meta-analyses confirm moderate effectiveness of non-opioid analgesics including NSAIDs and acetaminophen for nociceptive pain (30-40% pain reduction), while anticonvulsants and antidepressants show superior efficacy for neuropathic conditions (40-60% pain reduction) [78]. Opioid analgesics provide significant short-term relief but demonstrate limited long-term efficacy, with systematic reviews showing minimal improvement in pain and function beyond 3 months of therapy [79]. Combination pharmacotherapy targeting multiple pain mechanisms yields superior outcomes compared to monotherapy, with properly selected combinations achieving 15-25% greater pain reduction than single agents [80]. Safety considerations significantly impact treatment

selection, with growing evidence that risk stratification tools can identify patients at elevated risk for medication-related adverse outcomes with 70-80% accuracy [81]. Psychosocial factors substantially influence treatment response, with depression, anxiety, and catastrophizing predicting poorer outcomes across all pharmacological interventions, underscoring the necessity of concurrent psychological management [82].

Practical Recommendations for Clinicians

Implementation of effective pharmacological management requires systematic clinical approaches. Comprehensive initial assessment should include standardized pain measurement, functional impact evaluation, psychological screening, and risk factor identification before initiating therapy [83]. Medication selection should follow a mechanism-based algorithm, matching specific agents to identified pain types while considering comorbidities, with neuropathic components necessitating early consideration of adjuvant medications [84]. Start low, go slow dosing strategies minimize adverse effects while establishing minimum effective doses, particularly in elderly patients and those with hepatic or renal impairment [85]. Regular reassessment using validated outcome measures should evaluate not only pain intensity but also functional improvement, with continuation contingent upon demonstrable benefit and acceptable side effects [86]. De-prescribing protocols for ineffective or poorly tolerated medications prevent unnecessary polypharmacy, with gradual tapering preventing withdrawal syndromes while allowing evaluation of continued necessity [87]. Patient education regarding realistic expectations, proper medication use, and self-management strategies substantially improves outcomes and reduces adverse events [88].

Future Research Priorities

Several critical knowledge gaps require investigation to advance pharmacological pain management. Comparative effectiveness

research evaluating head-to-head performance of medication classes across specific pain conditions would address the current scarcity of direct comparison data and enhance evidence-based selection [89]. Precision medicine approaches integrating genetic, molecular, and clinical biomarkers to predict individual treatment responses represent a promising avenue for optimizing therapeutic selection [90]. Novel analgesic development targeting recently identified pain mechanisms, including specific ion channels and immune modulators, offers potential breakthroughs for currently refractory conditions [91]. Long-term outcome studies addressing the sustained effectiveness of pharmacological interventions beyond typical 12-week trial durations would provide critical data regarding maintenance strategies [92]. Research into optimal integration of pharmacological approaches with emerging technologies, including digital therapeutics and advanced neuromodulation, could yield synergistic pain management paradigms [93]. Implementation science investigating strategies to improve guideline adherence and reduce disparities in pain treatment would translate existing knowledge into improved clinical outcomes [94].

REFERENCES

1. Treede RD, Rief W, Barke A, et al. A classification of chronic pain for ICD-11. *Pain*. 2015;156(6):1003-1007.
2. Turkistani A. A systematic review of pharmacological interventions for chronic pain management. *South Eastern European Journal of Public Health*. 2024;22(1):45-62.
3. Mills SEE, Nicolson KP, Smith BH. Chronic pain: a review of its epidemiology and associated factors in population-based studies. *Br J Anaesth*. 2019;123(2).
4. Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. *Lancet*. 2021;397(10289):2082-2097.
5. Edwards RR, Dworkin RH, Sullivan MD, et al. The role of psychosocial processes in the development and maintenance of chronic pain. *J Pain*. 2016;17(9).
6. Pitcher MH, Von Korff M, Bushnell MC, Porter L. Prevalence and profile of high-impact chronic pain in the United States. *J Pain*. 2019;20(2):146-160.
7. Gerrits MM, van Oppen P, van Marwijk HW, et al. Pain and the onset of depressive and anxiety disorders. *Pain*. 2014;155(1):53-59.
8. Finan PH, Goodin BR, Smith MT. The association of sleep and pain: an update and a path forward. *J Pain*. 2013;14(12):1539-1552.
9. Gaskin DJ, Richard P. The economic costs of pain in the United States. *J Pain*. 2012;13(8):715-724.
10. Institute of Medicine. *Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research*. Washington, DC: National Academies Press; 2011.
11. Finnerup NB, Kuner R, Jensen TS. Neuropathic pain: from mechanisms to treatment. *Physiol Rev*. 2021;101(1):259-301.
12. Kamerman PR, Finnerup NB, De Lima L, et al. A definition of "chronic pain" for research and clinical practice. *Pain Rep*. 2023;8(1).
13. Birkinshaw H, Friedrich C, Cole P, et al. Antidepressants for pain management in adults with chronic pain: a network meta-analysis. *Health Technol Assess*. 2024;28(62):1-155.
14. Clauw DJ, Essex MN, Pitman V, Jones KD. Reframing chronic pain as a disease, not a symptom: rationale and implications for pain management. *Postgrad Med*. 2019;131(3):185-198.
15. Checa-Peñalver A, Lirio-Romero C, Luiz Ferreira EA, et al. Effectiveness of non-pharmacological interventions in the management of pediatric chronic pain: a systematic review. *Children*. 2024;11(3):382.

16. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. *Ann Intern Med.* 2004;140(6):441-451.
17. Ji RR, Chamesian A, Zhang YQ. Pain regulation by non-neuronal cells and inflammation. *Science.* 2016;354(6312):572-577.
18. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. *Cell.* 2009;139(2):267-284.
19. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. *J Pain.* 2009;10(9):895-926.
20. Kuner R, Flor H. Structural plasticity and reorganisation in chronic pain. *Nat Rev Neurosci.* 2016;17(1):20-30.
21. Finnerup NB, Haroutounian S, Kamerman P, et al. Neuropathic pain: an updated grading system for research and clinical practice. *Pain.* 2016;157(8):1599-1606.
22. Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. *Nat Rev Dis Primers.* 2017;3:17002.
23. Bennett DL, Clark AJ, Huang J, et al. The role of voltage-gated sodium channels in pain signaling. *Physiol Rev.* 2019;99(2):1079-1151.
24. Tsuda M. Microglia in the spinal cord and neuropathic pain. *J Diabetes Investig.* 2016;7(1):17-26.
25. Chen G, Zhang YQ, Qadri YJ, et al. Microglia in pain: detrimental and protective roles in pathogenesis and resolution of pain. *Neuron.* 2018;100(6):1292-1311.
26. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol.* 2015;14(2):162-173.
27. Williams AC, Craig KD. Updating the definition of pain. *Pain.* 2016;157(11):2420-2423.
28. Wiech K. Deconstructing the sensation of pain: the influence of cognitive processes on pain perception. *Science.* 2016;354(6312):584-587.
29. Ossipov MH, Morimura K, Porreca F. Descending pain modulation and chronification of pain. *Curr Opin Support Palliat Care.* 2014;8(2):143-151.
30. Kosek E, Cohen M, Baron R, et al. Do we need a third mechanistic descriptor for chronic pain states? *Pain.* 2016;157(7):1382-1386.
31. Kosek E, Clauw D, Nijs J, et al. Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system. *Pain.* 2021;162(11):2629-2634.
32. Gatchel RJ, McGeary DD, McGeary CA, Lippe B. Interdisciplinary chronic pain management: past, present, and future. *Am Psychol.* 2014;69(2):119-130.
33. Machado GC, Maher CG, Ferreira PH, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. *BMJ.* 2015;350.
34. da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. *Lancet.* 2017;390(10090).
35. Busse JW, Wang L, Kamaleldin M, et al. Opioids for chronic noncancer pain: a systematic review and meta-analysis. *JAMA.* 2018;320(23):2448-2460.
36. Häuser W, Petzke F, Üçeyler N, Sommer C. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. *Rheumatology.* 2011;50(3):532-543.
37. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. *Cochrane Database Syst Rev.* 2017;6(6).

38. Yoon E, Babar A, Choudhary M, et al. Acetaminophen-induced hepatotoxicity: a comprehensive update. *J Clin Transl Hepatol*. 2016;4(2):131-142.
39. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet*. 2013;382(9894):769-779.
40. Volkow ND, McLellan AT. Opioid abuse in chronic pain—misconceptions and mitigation strategies. *N Engl J Med*. 2016;374(13):1253-1263.
41. Riediger C, Schuster T, Barlinn K, et al. Adverse effects of antidepressants for chronic pain: a systematic review and meta-analysis. *Front Neurol*. 2017;8:307.
42. Zaccara G, Giovannelli F, Giorgi FS, et al. Tolerability of new antiepileptic drugs: a network meta-analysis. *Eur J Clin Pharmacol*. 2017;73(7):811-817.
43. Katz P, Andersen M, Cabrera C, et al. Real-world evaluation of direct and indirect economic burden among endometriosis patients in the United States. *Adv Ther*. 2019;36(10):2748-2761.
44. Chowdhury AR, Graham PL, Schofield D, et al. Productivity outcomes from chronic pain management interventions in the working age population: a systematic review. *Pain*. 2024;165(6):1233-1246.
45. Armstrong EP, Malone DC, McCarberg B, et al. Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia. *Curr Med Res Opin*. 2011;27(5):939-950.
46. Fan K, Fan Z, Li F, et al. Cost effectiveness of pharmacological management for osteoarthritis: a systematic review. *Pharmacoeconomics*. 2023;41(5):557-570.
47. Pike J, Sadosky A, Stacey BR, et al. The costs of nonprescription analgesics for chronic pain: a reference case from the United States. *J Med Econ*. 2012;15(4):763-771.
48. Krebs EE, Lorenz KA, Bair MJ, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. *J Gen Intern Med*. 2009;24(6):733-738.
49. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. *Pain Med*. 2005;6(6):432-442.
50. Baron R, Maier C, Attal N, et al. Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. *Pain*. 2017;158(2):261-272.
51. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. *Arch Intern Med*. 2003;163(20):2433-2445.
52. McLachlan AJ, Bath S, Naganathan V, et al. Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment. *Br J Clin Pharmacol*. 2011;71(3):351-364.
53. Trescot AM, Faynboym S. A review of the role of genetic testing in pain medicine. *Pain Physician*. 2014;17(5):425-445.
54. Yang Z, Yang Z, Arheart KL, et al. CYP2D6 poor metabolizer genotype and smoking predict severe postoperative pain in female patients on arrival to the recovery room. *Pain Med*. 2012;13(4):604-609.
55. Kringel D, Lötsch J. Pain, genetics, and locus of control. *Pain Rep*. 2018;3(3).
56. Dib-Hajj SD, Waxman SG. Translational pain research: lessons from genetics and genomics. *Sci Transl Med*. 2019;11(520).
57. Otdelenov VA, Denisenko NP, Sobur NI, et al. Practical issues in postoperative pain management: pain assessment and personalized choice of analgesics (review). *N.N. Priorov Journal of Traumatology and Orthopedics*. 2025;25(1):78-92.
58. Kamper SJ, Apeldoorn AT, Chiarotto A, et al. Multidisciplinary biopsychosocial

- rehabilitation for chronic low back pain: Cochrane systematic review and meta-analysis. *BMJ*. 2015;350.
59. Vink J, Morton D, Ferreri S. Pharmacist-led medication reviews in primary care. *Am J Manag Care*. 2011;17(7).
 60. Hylands-White N, Duarte RV, Raphael JH. An overview of treatment approaches for chronic pain management. *Rheumatol Int*. 2017;37(1):29-42.
 61. Thompson A, Umana J, Sabrick JB, et al. Innovative model for creation and use of co-developed pain management plans for patients with sickle cell disease. *Blood*. 2024;143(10):1057-1066.
 62. Dach A, Anderson R, Borandi JA. An integrative, non-pharmacological pain management approach in severe lumbar spine degeneration: a case report. *Integr Med*. 2024;23(6):14-20.
 63. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. *JAMA*. 2016;315(15):1624-1645.
 64. Lin LA, Bohnert AS, Kerns RD, et al. Impact of the opioid safety initiative on opioid-related prescribing in veterans. *Pain*. 2017;158(5):833-839.
 65. Alexander GC, Frattaroli S, Gielen AC, eds. The prescription opioid epidemic: an evidence-based approach. Johns Hopkins Bloomberg School of Public Health; 2015.
 66. Hodgson A. Considerations for the implementation of a non-pharmacological, patient-centered approach to chronic non-oncological pain treatment in the UK and Chile. *Revista Confluencia*. 2024;4(1):167-174.
 67. De Lima L, Pastrana T, Radbruch L, Wenk R. Cross-sectional pilot study to monitor the availability, dispensed prices, and affordability of opioids around the globe. *J Pain Symptom Manage*. 2014;48(4):649-659.
 68. Lagisetty PA, Healy N, Garpestad C, et al. Access to primary care clinics for patients with chronic pain receiving opioids. *JAMA Netw Open*. 2019;2(7).
 69. Algharably E, Budnick A, Dräger D, et al. Deficits in pain medication in older adults with chronic pain receiving home care: a cross-sectional study in Germany. *PLoS One*. 2020;15(2).
 70. Anderson KO, Green CR, Payne R. Racial and ethnic disparities in pain: causes and consequences of unequal care. *J Pain*. 2009;10(12):1187-1204.
 71. Kroenke K, Krebs EE, Wu J, et al. Stepped care to optimize pain care effectiveness (SCOPE) trial study design and sample characteristics. *Contemp Clin Trials*. 2013;34(2):270-281.
 72. Leung D, Fong APC, Wong FH, et al. Non-pharmacological interventions for chronic pain in older adults: a systematic review and meta-analysis. *Gerontologist*. 2024;64(4):757-769.
 73. Ballantyne JC, Sullivan MD. Intensity of chronic pain—the wrong metric? *N Engl J Med*. 2015;373(22):2098-2099.
 74. Meghani SH, Byun E, Gallagher RM. Time to take stock: a meta-analysis and systematic review of analgesic treatment disparities for pain in the United States. *Pain Med*.
 75. Meghani SH, Byun E, Gallagher RM. Time to take stock: a meta-analysis and systematic review of analgesic treatment disparities for pain in the United States. *Pain Med*. 2012;13(2):150-174.
 76. Bindicsova I, Hides L, Day MA. An in-depth exploration of consumer and consumer representative views on chronic pain management in Australia: a key informant interview study. *J Pain Palliat Care Pharmacother*. 2024;38(1):1-10.
 77. Giordano NA, Lofland JH, Gudin J, et al. Patient satisfaction with analgesic medications: relationships with pain, side effects, and medication-taking behavior. *J Opioid Manag*. 2020;16(5):345-357.
 78. Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult

- patients: ESMO clinical practice guidelines. *Ann Oncol.* 2018;29(Suppl 4).
79. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. *Pain.* 2010;150(3):573-581.
 80. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. *Ann Intern Med.* 2015;162(4):276-286.
 81. Gilron I, Jensen TS, Dickenson AH. Combination pharmacotherapy for management of chronic pain: from bench to bedside. *Lancet Neurol.* 2013;12(11):1084-1095.
 82. Turk DC, Fillingim RB, Ohrbach R, Patel KV. Assessment of psychosocial and functional impact of chronic pain. *J Pain.* 2016;17(9).
 83. Edwards RR, Dworkin RH, Turk DC, et al. Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. *Pain.* 2016;157(9):1851-1871.
 84. Pereira MP, Doyle T, Viet CT, et al. Implementation of a standardized pain assessment in a cancer centre's outpatient palliative care clinic. *BMJ Open Qual.* 2019;8(3).
 85. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. *Lancet Neurol.* 2010;9(8):807-819.
 86. Ferrell B, Argoff CE, Epplin J, et al. Pharmacological management of persistent pain in older persons. *J Am Geriatr Soc.* 2009;57(8):1331-1346.
 87. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. *Pain.* 2005;113(1-2):9-19.
 88. Bressilver M, Angres MA, Frank JW. Tapering long-term opioid therapy in chronic noncancer pain: evidence and recommendations for everyday practice. *Mayo Clin Proc.* 2018;93(9):1223-1236.
 89. Fontoura GMG, Andrade Filho AS, Abdon BL, et al. The singular therapeutic project as a learning and comprehensive care tool: experience report on the management of chronic pain in an elderly patient. *IOSR Journal of Nursing and Health Science.* 2024;13(2):35-42.
 90. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J.* 2020;41(1):111-188.
 91. Robinson CL, D'souza R, Yazdi C, et al. Reviewing the potential role of artificial intelligence in delivering personalized and interactive pain medicine education for chronic pain patients. *J Pain Res.* 2024;17:923-929.
 92. Diotaiuti P, Corrado S, Tosti B, et al. Evaluating the effectiveness of neurofeedback in chronic pain management: a narrative review. *Front Psychol.* 2024;15:1288401.
 93. Williams T-L, Joseph C, Nilsson-Wikmar L, Phillips J. Guidelines for chronic pain in adult spinal cord injury population: scoping review. *S Afr J Physiother.* 2024;80(1):1923.
 94. Strain JDR, Welch L, Sadler E. Systematic review and narrative synthesis of the experiences of individuals with chronic pain participating in digital pain management interventions. *PLoS One.* 2024;19(1).
 95. Musso-Daury L, Fernández TP, López-Ortiz S, et al. Conservative, non-pharmacological interventions for pain management in juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized controlled trials. *Cureus.* 2024;16(1).